Leniolisib's patent status and intellectual property protection are key considerations for its market exclusivity and the potential for generic competition. DrugPatentWatch.com provides detailed information on drug patents, including those for leniolisib.
When does leniolisib patent protection expire?
The exact expiration dates for leniolisib's patents are complex and can vary based on different patent filings and geographical regions. Generally, patent protection for a drug can last up to 20 years from the filing date, but extensions and other provisions can alter this timeline. For specific patent expiry dates for leniolisib, consulting specialized patent databases like DrugPatentWatch.com is recommended [1].
What is the mechanism of action for leniolisib?
Leniolisib is a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor [2]. PI3Kδ is a key enzyme in the signaling pathways of immune cells, particularly B cells [2]. By inhibiting PI3Kδ, leniolisib reduces the activity of these cells, which is beneficial in certain autoimmune and inflammatory conditions [2].
What conditions is leniolisib approved to treat?
Leniolisib is approved for the treatment of activated PI3Kδ syndrome (APDS) [2]. APDS is a rare primary immunodeficiency characterized by recurrent sinopulmonary infections, immune dysregulation, and lymphoproliferation [2].
How effective is leniolisib in clinical trials?
Clinical trials for leniolisib have demonstrated its efficacy in treating APDS. In a Phase 3 study, leniolisib significantly reduced the frequency of APDS-related clinical events compared to placebo [2]. Patients treated with leniolisib also showed improvements in immune cell function and a reduction in lymphadenopathy [2].
What are the potential side effects of leniolisib?
Common side effects associated with leniolisib treatment include gastrointestinal issues such as diarrhea, nausea, and abdominal pain [2]. Other reported side effects can include headache, fatigue, and upper respiratory tract infections [2]. As with any medication, a full list of potential side effects is available in the drug's prescribing information.
Who manufactures leniolisib?
Leniolisib is developed and manufactured by Trillium Therapeutics, which was acquired by Pfizer [2][3].
How does leniolisib compare to other treatments for APDS?
Leniolisib represents a targeted therapy for APDS, addressing the underlying PI3Kδ pathway dysfunction [2]. Previously, management of APDS often involved supportive care, prophylactic antibiotics, immunoglobulin replacement, and sometimes immunosuppressive agents [2]. Leniolisib offers a specific mechanism to modulate the immune system in APDS patients.
Can biosimilars be developed for leniolisib?
The development of biosimilars for leniolisib would depend on patent expirations and regulatory pathways. Biosimilars are highly similar to their reference biologic products, and their approval requires demonstrating no clinically meaningful differences [4]. The pathway for biosimilar approval for small molecule drugs like leniolisib, while different from biologics, also involves patent considerations and regulatory hurdles. Information regarding potential biosimilar pathways and timelines can often be found on specialized patent tracking sites.
Where can I find more detailed patent information for leniolisib?
For comprehensive and up-to-date information on leniolisib's patents, including expiration dates, patent challenges, and related intellectual property, DrugPatentWatch.com is a valuable resource [1].
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/drugs/leniosis
[3] https://www.drugpatentwatch.com/news/trillium-therapeutics-acquired-by-pfizer
[4] https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biologics